Gonadorelin: research, legal status and who sells it
This page is information, not medical advice. Some Gonadorelin products are approved prescription drugs; research-grade versions sold online are not those products. We don't publish dosing or usage instructions.
- Also known as
- GnRH, Factrel, Lutrepulse
- Category
- Synthetic gonadotropin-releasing hormone
- Evidence level
- Approved drug (in at least one market)
- Approved products
- Factrel (discontinued) (US); Lutrepulse (discontinued) (US); HRF (gonadorelin) (UK); Kryptocur, Lutrelef and others (national authorisations) (EU)
- Price range
- $3.75/mg to $12.50/mg, median $6.57/mg across 10 vendors (compare)
- Our lab tests
- None yet (how testing will work)
Legal and regulatory status
| Where | Status |
|---|---|
| United States | Approved as Factrel and Lutrepulse in the past; both applications are listed as discontinued [1][2]. |
| United Kingdom | Licensed as HRF (gonadorelin) [3]. |
| European Union | Authorized nationally in Austria, France, Germany, Italy and the Netherlands [4]. |
| Canada | Human gonadorelin products are cancelled or dormant; current marketed listings are veterinary [5][6]. |
| Australia | Schedule 4 (prescription-only) in Australia's Poisons Standard [7]. |
| Sport (WADA) | Prohibited at all times in males under S2 [8]. |
We haven't published a full overview of Gonadorelin yet. The legal status table and live prices on this page are current.
Gonadorelin prices: cheapest listings
The five lowest $/mg listings out of 13. See all Gonadorelin prices
| Vendor | Transparency | Product | Size | Price | $/mg | Stock | Vendor's page |
|---|---|---|---|---|---|---|---|
| Chimera Peptides | 27 | 2 mg × 20 | $150 | $3.75/mg | View | ||
| Chimera Peptides | 27 | 2 mg × 10 | $85 | $4.25/mg | View | ||
| Bulk Peptide Supply | 57 | 10 mg × 10 | $450 | $4.50/mg | View | ||
| Peptide Maxxing | 40 | 10 mg | $65 | $6.50/mg | View | ||
| Paramount Peptides | 65 | 10 mg | $65 | $6.54/mg | View |
Sources
- Drugs@FDA: NDA 018123 (Factrel), discontinued. U.S. Food and Drug Administration. Accessed Oct 14, 2026
- Drugs@FDA: NDA 019687 (Lutrepulse), discontinued. U.S. Food and Drug Administration. Accessed Oct 14, 2026
- MHRA Products: licensed-medicine search for "gonadorelin". Medicines and Healthcare products Regulatory Agency (UK). Accessed Oct 14, 2026
- EMA Article 57 product data: medicines authorised in the EU/EEA (data as of 9 October 2026). European Medicines Agency. Accessed Oct 14, 2026
- Drug Product Database: Lutrepulse (gonadorelin), status Dormant. Health Canada. Accessed Oct 14, 2026
- Drug Product Database online query (searched by active ingredient). Health Canada. Accessed Oct 14, 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327, registered 30 September 2026). Federal Register of Legislation, Australian Government. Accessed Oct 14, 2026
- World Anti-Doping Code International Standard: Prohibited List 2026 (in force 1 January 2026). World Anti-Doping Agency. Accessed Oct 14, 2026